<DOC>
	<DOC>NCT02224768</DOC>
	<brief_summary>To evaluate the effectiveness of the YERVOY® educational Risk Minimization (RM) tools in terms of awareness about these tools, their utilization, knowledge and comprehension of Immune Related Adverse Reaction (irAR)s, and appropriate behavior by Healthcare Professional (HCP)s and patients</brief_summary>
	<brief_title>YERVOY® Risk Minimization Tool Effectiveness Evaluation Survey</brief_title>
	<detailed_description>A total sample size of 160 to 200 HCPs and 160 to 200 patients</detailed_description>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com HCP experienced in the treatment of patients with the research compound and patients that have received at least one dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>